Payment overview · 2025
General Payments
$739.65
18 reported records · 9 companies
Healthcare provider profile · identity verified
Joshua Mark Evans, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · BOWIE, TX · NPI 1376830539
Verified facts
What the public records show
CMS Open Payments records show Joshua Mark Evans, D.O. received $739.65 in general payments during 2025 across 18 reported records.
GM Pharmaceuticals, Inc. accounted for 47.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 261 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GM Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $349.77 | 47.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $239.68 | 32.4% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.45 | 5.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.84 | 3.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.72 | 2.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.81 | 2.3% | 1 | 2025 |
| Optos, Inc. | Unresolved — no canonical attribution shown | $15.82 | 2.1% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.41 | 2.1% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $14.15 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $723.83 | 17 |
| Entertainment | $15.82 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Vanacof Normalized: vanacof |
Drug | GM Pharmaceuticals, Inc. | $349.77 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $239.68 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.45 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $27.84 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| NFC-700 Normalized: nfc 700 |
Device | Optos, Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| OCT OPHTHALMOSCOPE Normalized: oct ophthalmoscope |
Device | Optos, Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| PANORAMIC OPHTHALMOSCOPE Normalized: panoramic ophthalmoscope |
Device | Optos, Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 261 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
261 | 56 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 895 | 226 |
| Levothyroxine Sodium | Levothyroxine Sodium | 699 | 164 |
| Losartan Potassium | Losartan Potassium | 658 | 180 |
| Lisinopril | Lisinopril | 583 | 159 |
| Alprazolam | Alprazolam | 517 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 492 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 474 | 138 |
| Furosemide | Furosemide | 427 | 128 |
| Potassium Chloride | Potassium Chloride | 415 | 112 |
| Gabapentin | Gabapentin | 405 | 115 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 316 | 68 |
| Tramadol Hcl | Tramadol Hcl | 316 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 295 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 287 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 286 | 82 |
| Trazodone Hcl | Trazodone Hcl | 282 | 69 |
| Pravastatin Sodium | Pravastatin Sodium | 266 | 78 |
| Ozempic | Semaglutide | 261 | 56 |
| Methylprednisolone | Methylprednisolone | 255 | 197 |
| Omeprazole | Omeprazole | 251 | 70 |
| Clopidogrel | Clopidogrel Bisulfate | 247 | 58 |
| Metformin Hcl | Metformin Hcl | 241 | 62 |
| Carvedilol | Carvedilol | 235 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 232 | 57 |
| Eliquis | Apixaban | 221 | 50 |
| Celecoxib | Celecoxib | 220 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 210 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 205 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 200 | 39 |
| Meloxicam | Meloxicam | 195 | 60 |
| Sertraline Hcl | Sertraline Hcl | 194 | 64 |
| Pregabalin | Pregabalin | 188 | 36 |
| Allopurinol | Allopurinol | 187 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 185 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 50 |
| Simvastatin | Simvastatin | 168 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 164 | 25 |
| Montelukast Sodium | Montelukast Sodium | 158 | 44 |
| Nifedipine Er | Nifedipine | 155 | 45 |
| Temazepam | Temazepam | 154 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 140 | 33 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 132 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 132 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 127 | 30 |
| Donepezil Hcl | Donepezil Hcl | 122 | 27 |
| Alendronate Sodium | Alendronate Sodium | 117 | 37 |
| Buspirone Hcl | Buspirone Hcl | 117 | 31 |
| Jardiance | Empagliflozin | 112 | 31 |
| Clonazepam | Clonazepam | 109 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 106 | 24 |
| Eszopiclone | Eszopiclone | 103 | 28 |
| Glimepiride | Glimepiride | 101 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 22 |
| Diazepam | Diazepam | 99 | 22 |
| Memantine Hcl | Memantine Hcl | 99 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 97 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 23 |
| Levetiracetam | Levetiracetam | 95 | 19 |
| Spironolactone | Spironolactone | 91 | 28 |
| Azithromycin | Azithromycin | 87 | 79 |
| Aripiprazole | Aripiprazole | 84 | 15 |
| Lovastatin | Lovastatin | 83 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 83 | 60 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 16 |
| Cefuroxime | Cefuroxime Axetil | 80 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 19 |
| Lorazepam | Lorazepam | 77 | 15 |
| Myrbetriq | Mirabegron | 75 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 15 |
| Mirtazapine | Mirtazapine | 74 | 17 |
| Divalproex Sodium | Divalproex Sodium | 73 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 72 | 24 |
| Humalog Kwikpen U-100 | Insulin Lispro | 72 | 11 |
| Warfarin Sodium | Warfarin Sodium | 70 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 20 |
| Mounjaro | Tirzepatide | 66 | 14 |
| Digoxin | Digoxin | 63 | 14 |
| Synthroid | Levothyroxine Sodium | 62 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 59 | 12 |
| Clonidine Hcl | Clonidine Hcl | 59 | 25 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 59 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | 12 |
| Metformin Hcl Er | Metformin Hcl | 58 | 20 |
| Finasteride | Finasteride | 57 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 17 |
| Oxcarbazepine | Oxcarbazepine | 56 | suppressed |
| Trulicity | Dulaglutide | 55 | suppressed |
| Glipizide | Glipizide | 54 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 34 |
| Atenolol | Atenolol | 50 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 50 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 24 |
| Nystatin | Nystatin | 49 | 24 |
| Enalapril Maleate | Enalapril Maleate | 46 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 46 | 14 |
| Gemtesa | Vibegron | 46 | suppressed |
| Methocarbamol | Methocarbamol | 46 | 15 |
| Bupropion Xl | Bupropion Hcl | 45 | 11 |
| Topiramate | Topiramate | 45 | suppressed |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Estradiol | Estradiol | 43 | 14 |
| Promethazine Hcl | Promethazine Hcl | 42 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 13 |
| Prednisone | Prednisone | 41 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Mupirocin | Mupirocin | 40 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Linzess | Linaclotide | 39 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Famotidine | Famotidine | 36 | 13 |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 35 | suppressed |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Valsartan | Valsartan | 35 | 11 |
| Baclofen | Baclofen | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 23 |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 16 |
| Novolog Flexpen | Insulin Aspart | 34 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 15 |
| Primidone | Primidone | 31 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 18 |
| Metolazone | Metolazone | 29 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Calcitriol | Calcitriol | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 17 |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 18 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 19 |
| Mitigare | Colchicine | 26 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Klor-Con 10 | Potassium Chloride | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 23 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 12 |
| Latanoprost | Latanoprost | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Zonisamide | Zonisamide | 16 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 15 | 15 |
| Colchicine | Colchicine | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 13 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 13 | 12 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Rinvoq | Upadacitinib | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Isentress | Raltegravir Potassium | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $739.65 · 18 records | GM Pharmaceuticals, Inc. | CAPLYTA, INSPIRE, Korlym, NFC-700, OCT OPHTHALMOSCOPE, Ozempic, PANORAMIC OPHTHALMOSCOPE, Qelbree, REXULTI, Rybelsus, Vanacof, XYOSTED | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lundbeck LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error